Recent analyst commentary on Guardian Pharmacy Services (GRDN) has focused on the company’s operational efficiency, financial flexibility, and technology platform, with several firms reiterating positive views on its potential for growth through both organic expansion and acquisitions.

Guardian Pharmacy Services’ share price has risen strongly over 2026, with a year to date share price return of 43.62% and a 1 year total shareholder return of 115.50%. This suggests momentum has been building even after recent short term pullbacks.

If you are weighing Guardian Pharmacy Services against other opportunities, it can help to see what else is gaining attention in healthcare technology and services, starting with 41 healthcare AI stocks

With Guardian Pharmacy Services trading near analyst targets and only a modest intrinsic discount indicated, the key question is whether recent gains leave limited upside or the market is still underestimating future growth potential and a possible buying opportunity.

Price-to-Earnings of 50.6x: Is it justified?

Guardian Pharmacy Services currently trades on a P/E of 50.6x, which is lower than a peer average of 82.6x but higher than both the wider US Healthcare industry and an estimated fair P/E level.

The P/E ratio compares the current share price to earnings per share, so it effectively shows how much investors are paying for each dollar of Guardian Pharmacy Services’ earnings. For a business that has only recently become profitable and operates in healthcare technology and services, a higher P/E can reflect the market’s willingness to pay up for earnings that analysts expect to grow.

Here, the picture is mixed. On one hand, Guardian Pharmacy Services screens as good value relative to similar companies on a P/E of 50.6x versus a peer average of 82.6x, which suggests investors are paying less for each dollar of earnings than they are for those peers. On the other hand, the same 50.6x multiple is significantly higher than the wider US Healthcare industry average of 22.7x and also well above an estimated fair P/E of 23.9x that the market could move toward if expectations reset.

Result: Preferred multiple of Price-to-Earnings of 50.6x (OVERVALUED)

However, Guardian Pharmacy Services still faces risks related to its relatively high P/E multiple, as well as the possibility that long term care facility spending or reimbursement frameworks tighten.

Another View on Guardian Pharmacy Services’ Value

While Guardian Pharmacy Services looks expensive on a 50.6x P/E compared with the US Healthcare industry at 22.7x and a fair ratio of 23.9x, it still trades below a peer average of 82.6x. That gap points to valuation risk if sentiment cools, but also leaves room if peers remain the benchmark.

For a closer look at what this gap could mean in practice, check the detailed valuation breakdown in the See what the numbers say about this price — find out in our valuation breakdown.

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Guardian Pharmacy Services for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 45 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

Given the mix of optimism and caution around Guardian Pharmacy Services, it makes sense to look at the data yourself and decide where you stand. To weigh the upside potential against the areas investors are watching more closely, start by checking the 3 key rewards and 1 important warning sign.

Looking for more Guardian Pharmacy Services style investment ideas?

If Guardian Pharmacy Services has caught your attention, do not stop here. There is a wider set of opportunities you can size up before making your next move.

• Spot potential value opportunities early by scanning 45 high quality undervalued stocks, which combine quality fundamentals with prices that may not fully reflect those traits.
• Prioritise resilience in tougher markets by reviewing 66 resilient stocks with low risk scores, which have lower risk scores and steadier profiles.
• Hunt for lesser known opportunities by checking screener containing 20 high quality undiscovered gems, which pair solid fundamentals with relatively limited market attention.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.